[2]Brasó-Maristany F,et al. Patritumab deruxtecan in HER2-negative breast cancer: part B results of the window-of-opportunity SOLTI-1805 TOT-HER3 trial and biological determinants of early response. Nat Commun. 2024 Jul 11;...
参考文献: [1]Brasó-Maristany F, Ferrero-Cafiero JM, Falato C, et al. Patritumab deruxtecan in HER2-negative breast cancer: part B results of the window-of-opportunity SOLTI-1805 TOT-HER3 trial and biological determinants of early response. Nat Commun. 2024;15(1):5826. Published 2024 ...
RESULTS: One hundred eighty-two enrolled patients received ≥1 dose of HER3-DXd. Patients had a median of five previous therapies for advanced disease. Efficacy results are reported across clinical subtypes: hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-neg...
[1]Brasó-Maristany F, Ferrero-Cafiero JM, Falato C, et al. Patritumab deruxtecan in HER2-negative breast cancer: part B results of the window-of-opportunity SOLTI-1805 TOT-HER3 trial and biological determinants...
Keyword:Her-2 negative breast cancer;Neoadjuvant chemotherapy;Efficacy assessment; Untoward effect ;Prognostic evaluation 0 引言 当前,随着社会各方面飞速发展进步,快节奏的生活,工作状态使得身体及心理负担加重,伴随整个社会人口老龄化的持续加剧,近几年来,我国癌症负担明显加重,癌症的发病率和死亡率逐年上升[1] 。
Prognosis of HER-2 -positive, as compared to HER-2 -negative, disease is poorer. But by adding HER-2 signaling pathway inhibitors, including trastuzumab, to standard chemotherapy, we can change this poor outcome. Given that more than three of four patients diagnosed with breast cancer have a...
Patritumab deruxtecan in HER2-negative breast cancer: part B results of the window-of-opportunity SOLTI-1805 TOT-HER3 trial and biological determinants of early response Fara Brasó-Maristany, Juan Manuel Ferrero-Cafiero, Claudette Falato, Olga Martínez-Sáez, Juan Miguel Cejalvo, Mireia...
三阴性乳腺癌(Triple negative Breast cancer,TNBC)的“三阴”是指雌激素受体(ER)、孕激素受体(PR)和人表皮生长因子受体(Her-2)都没有表达。相比之下,三阴性乳腺癌治疗手段比较单一,主要依靠化疗。如果,只是常规的标准治疗,其预后依然很差,而且存在耐药的问题,无复发生存率和总生存率均相对较低。
Patritumab deruxtecan (HER3-DXd) is a promising therapy for breast cancer, targeting HER3. Here, the authors analyse the genomic factors that affect the response to HER3-DXd in patients with early-stage HER2-negative breast cancer as part of the SOLTI-1805 TOT-HER3 clinical trial and ...
01-关于her-2阴性胃癌治疗 根据现行国际各大指南标准[5]，铂类联合氟尿嘧啶类药物为基础的全身化疗是晚期 HER-2 阴性胃癌的一线标准治疗，且化疗通常持续至直至疾病进展。然而铂类药物的累积毒性通常会使患者的身体状态进一步恶化。临床中，患者持续化疗至出现无法耐受的毒性后，通常使用氟尿嘧啶类药物单药治疗。此外，...